SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-036461
Filing Date
2020-08-05
Accepted
2020-08-05 08:21:10
Documents
15
Period of Report
2020-08-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eypt-8k_20200805.htm   iXBRL 8-K 43119
2 EX-1.1 eypt-ex11_58.htm EX-1.1 318130
3 EX-5.1 eypt-ex51_16.htm EX-5.1 15327
4 GRAPHIC giscqqxzodjb000001.jpg GRAPHIC 2421
  Complete submission text file 0001564590-20-036461.txt   577034

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA eypt-20200805.xsd EX-101.SCH 5830
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE eypt-20200805_lab.xml EX-101.LAB 18719
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eypt-20200805_pre.xml EX-101.PRE 11223
8 EXTRACTED XBRL INSTANCE DOCUMENT eypt-8k_20200805_htm.xml XML 3421
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 201075719
SIC: 3826 Laboratory Analytical Instruments